Cargando…

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Rezafungin (CD101) is a novel echinocandin antifungal agent with activity against Aspergillus and Candida species, including azole- and echinocandin-resistant isolates. The objective of these analyses was to conduct pharmacokinetic (PK)-pharmacodynamic (PD) target attainment analyses to evaluate sin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bader, Justin C., Lakota, Elizabeth A., Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971579/ https://www.ncbi.nlm.nih.gov/pubmed/29555634 http://dx.doi.org/10.1128/AAC.02614-17

Ejemplares similares

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species
por: Locke, Jeffrey B., et al.
Publicado: (2018)

Pathogenesis and Virulence of Candida albicans and Candida glabrata
por: Henriques, Mariana, et al.
Publicado: (2020)

Phosphate in Virulence of Candida albicans and Candida glabrata
por: Köhler, Julia R., et al.
Publicado: (2020)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

Sugar Sensing and Signaling in Candida albicans and Candida glabrata
por: Van Ende, Mieke, et al.
Publicado: (2019)

Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report
por: Adeel, Alina, et al.
Publicado: (2021)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

Propargyl-Linked Antifolates are Dual Inhibitors of Candida albicans and Candida glabrata
por: G-Dayanandan, Narendran, et al.
Publicado: (2014)

The Effects of Cinnamaldehyde (Cinnamon Derivatives) and Nystatin on Candida Albicans and Candida Glabrata
por: Bakhtiari, Sedigheh, et al.
Publicado: (2019)

Morphological characteristics of Candida albicans, Candida krusei, Candida guilliermondii, and Candida glabrata biofilms, and response to farnesol
por: Sachivkina, Nadezhda, et al.
Publicado: (2021)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

The Anti-Virulence Effect of Vismia guianensis against Candida albicans and Candida glabrata
por: Motta, Elizangela Pestana, et al.
Publicado: (2022)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters
por: Lakota, Elizabeth A., et al.
Publicado: (2017)

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland
por: Coste, A. T., et al.
Publicado: (2020)

Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance
por: Grosset, Marine, et al.
Publicado: (2016)

Clonal evolution of Candida albicans, Candida glabrata and Candida dubliniensis at oral niche level in health and disease
por: Moorhouse, Alexander J., et al.
Publicado: (2021)

In vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis
por: Amirrajab, Nasrin, et al.
Publicado: (2023)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Candida glabrata Binding to Candida albicans Hyphae Enables Its Development in Oropharyngeal Candidiasis
por: Tati, Swetha, et al.
Publicado: (2016)

Iodine induces toxicity against Candida albicans and Candida glabrata through oxidative stress
por: Cuellar-Rufino, Sergio, et al.
Publicado: (2022)

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

Fluconazole impacts the extracellular matrix of fluconazole-susceptible and -resistant Candida albicans and Candida glabrata biofilms
por: Panariello, Beatriz Helena Dias, et al.
Publicado: (2018)

Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection
por: Pais, Pedro, et al.
Publicado: (2019)

Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing
por: Spettel, Kathrin, et al.
Publicado: (2019)

Decreasing Cell Population of Individual Candida Species Does Not Impair the Virulence of Candida albicans and Candida glabrata Mixed Biofilms
por: Li, Qianqian, et al.
Publicado: (2019)

Danish Whole-Genome-Sequenced Candida albicans and Candida glabrata Samples Fit into Globally Prevalent Clades
por: Szarvas, Judit, et al.
Publicado: (2021)

Is There a Relationship Between Mating and Pathogenesis in Two Human Fungal Pathogens, Candida albicans and Candida glabrata?
por: Bedekovic, Tina, et al.
Publicado: (2023)

Acetate modulates the inhibitory effect of Lactobacillus gasseri against the pathogenic yeasts Candida albicans and Candida glabrata
por: Pedro, Nuno A., et al.
Publicado: (2023)

Candida auris Cell Wall Mannosylation Contributes to Neutrophil Evasion through Pathways Divergent from Candida albicans and Candida glabrata
por: Horton, Mark V., et al.
Publicado: (2021)

Two unlike cousins: Candida albicans and C. glabrata infection strategies
por: Brunke, Sascha, et al.
Publicado: (2013)

Candida glabrata candidemia
por: Chakrabarti, Arunaloke
Publicado: (2015)

Adhesins in Candida glabrata
por: Timmermans, Bea, et al.
Publicado: (2018)

The Candida genome database incorporates multiple Candida species: multispecies search and analysis tools with curated gene and protein information for Candida albicans and Candida glabrata
por: Inglis, Diane O., et al.
Publicado: (2012)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

Molecular epidemiology of Candida albicans and Candida glabrata strains isolated from intensive care unit patients in Poland
por: Paluchowska, Paulina, et al.
Publicado: (2014)

Effect of Terminalia catappa Linn. on Biofilms of Candida albicans and Candida glabrata and on Changes in Color and Roughness of Acrylic Resin
por: Gonçalves, Letícia Machado, et al.
Publicado: (2019)

Antifungal Activity of a Hydroethanolic Extract From Astronium urundeuva Leaves Against Candida albicans and Candida glabrata
por: Bonifácio, Bruna Vidal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_omq5nti1a97go04l97ce6ekdtu